Literature DB >> 3907614

Blood pressure and plasma renin activity as predictors of orthostatic intolerance.

M H Harrison, S E Kravik, G Geelen, L Keil, J E Greenleaf.   

Abstract

Some physiological responses to head-up tilt and 3 h standing were evaluated in 13 dehydrated subjects. Seven of the subjects proved to be orthostatically intolerant (INT), exhibiting presyncopal symptoms. Before the symptoms manifest themselves the INT subjects had consistently lower (p less than 0.05) systolic blood pressures, generally lower diastolic and pulse pressures, and elevated (p less than 0.05) plasma renin activity (PRA) compared to the tolerant (TOL) subjects. Plasma vasopressin usually increased more in the INT subjects, but appeared to be related to the severity of presyncopal symptoms rather than to the upright posture per se. It is concluded that systolic and pulse pressures, with PRA, may allow discrimination between TOL, and potentially INT individuals; i.e., predict orthostatic intolerance. It is suggested that dehydration could provide a valuable physiological model for elucidating the causes of orthostatic intolerance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907614

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  3 in total

1.  Syncope as a health risk for soldiers - influence of medical history and clinical findings on the sensitivity of head-up tilt table testing.

Authors:  Hagen Frickmann; Sven Andreas Jungblut; Hans-Joachim Gilfrich; Lena Marie Heidelmann; Franziska Grube
Journal:  Mil Med Res       Date:  2015-12-02

2.  Efficacy of fluid loading as a countermeasure to the hemodynamic and hormonal changes of 28-h head-down bed rest.

Authors:  Heather Edgell; Anna Grinberg; Keith R Beavers; Nathalie Gagné; Richard L Hughson
Journal:  Physiol Rep       Date:  2018-09

Review 3.  Biology of Lymphedema.

Authors:  Bianca Brix; Omar Sery; Alberto Onorato; Christian Ure; Andreas Roessler; Nandu Goswami
Journal:  Biology (Basel)       Date:  2021-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.